Efficacy of amaranthus extract on male pattern hair loss

A randomized placebo controlled clinical trial to determine the efficacy of amaranthus extract on male pattern hair loss

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/07/043774

Enrollment

Registered

2022-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Amaranthus extract: 2g once daily at night for 90 days Control Intervention1: Placebo: 2g once daily at night for 90 days

Eligibility

Inclusion criteria

Inclusion criteria: Males 25 to 45 years of age with clinically diagnosed male pattern hair loss (MPHL) measured with Trichoscan. Willing to maintain the same hairstyle, hair length, and hair color during the entire study and refrain from cutting the scalp hair. Subjects willing to give written informed consent.

Exclusion criteria

Exclusion criteria: History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium or conditions other than androgenic alopecia. Any dermatological disorders of the scalp which might interfere with the application of Investigational Medical Product or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy or psychiatric disorder including trichotillomania. Subjects who have received radiation to the scalp, cancer treatment in the 6 months prior to start of the study or have a plan to do treatments during study. Evidence of hypogonadism defined as serum testosterone less than 250ng. Subjects who have had hair transplant or undergoing any medical treatments. Topical minoxidil, finasteride, phenytoin, 5 alpha reductase inhibitors, isotretinoin, or any other OTC, prescription medication topical or oral herbal supplement for hair growth or medications known to promote hair loss within the past 3 months. Current or within 2 weeks prior to first dosing use of vasodilating (e.g. Pentoxifylline, nitroglycerine), anticoagulating, immunosuppressive or corticosteroid drugs. Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test, STDs like Syphilis, autoimmune disorders, Diabetes mellitus, Coagulation or iron deficiencies, hypothyroidism or hyperthyroidism.

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in the Terminal hair (Non-Vellus hair) density (n/cm2), hair-shaft diameter (mm), and hair growth rate (mm/day)Timepoint: [ Time Frame: Baseline day3 to day 93]	—

Secondary

Measure	Time frame
1. Mean change from baseline in the Target area total hair count, thickness (mm) and length (mm) Timepoint: [ Time Frame: Baseline day3 to day 93]	—

Countries

India

Contacts

Public ContactSooraj Rajasekharan Kartha

Arjuna Natural Private Ltd

drbinu@arjunanatural.com09447818432

Outcome results